News
Home>
News
News
-
Media CoverageTa Kung Pao | Net Profit Doubles with 27.2% Surge in Innovative Product Revenue - SBP Group Announces 2025 Interim Results
Driven by the dual forces of policy support and innovation, the domestic pharmaceutical industry is accelerating its recovery. On August 18, Hong Kong-listed leading pharmaceutical company Sino Biopharmaceutical Limited (SBP Group, 01177.HK) announced its 2025 semi-annual results. In the first half of the year, the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively, marking three consecutive reporting periods of stable double-digit growth.2025-08-18 -
Media Coverage
China Securities Journal | SBP Group: Net Profit Up 140.2% YoY in H1, Innovative Product Revenue Up 27.2% YoY
China Securities Journal, cs.com.cn (Reporter: Meng Peijia) - The 2025 semi-annual results report disclosed by Sino Biopharmaceutical Limited (SBP Group,1177.HK) on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion in the first half of the year, representing year-on-year increases of 10.7% and 140.2%, respectively, achieving double-digit performance growth. The company proposes to distribute a dividend of RMB 820 million for the first half of 2025, an increase of over 60% compared to the same period last year.2025-08-18 -
Media Coverage
Xinhua News Agency | SBP Group Reports 140.2% YoY Growth in H1 2025 Net Profit Attributable to Owners of the Parent
Xinhua Finance, Nanjing, August 18 (Reporter: Zhu Cheng) - The 2025 semi-annual results report disclosed by Sino Biopharmaceutical Limited (SBP Group, 1177.HK) on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively.2025-08-18 -
Company News
SBP Group's Adalimumab Approved for Marketing in Algeria
Recently, the biosimilar Adalimumab (Brand name: Taibowei) from Chia Tai Tianqing, a member company of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), was officially approved for marketing by the Algerian Medicines Agency. This will bring a high-quality and affordable new treatment option to patients with autoimmune disorders in countries participating in the "Belt and Road" initiative.2025-08-11 -
Company NewsSBP Group Held Briefing on LaNova Medicines Acquisition and Detailed Potential Assets of Four Major Platforms
On the morning of July 17, Sino Biopharmaceutical Limited (SBP Group, 1177.HK), the parent company of Chia Tai Tianqing, held a briefing on the wholly-owned acquisition of LaNova Medicines.2025-07-18 -
Media Coverage
People's Daily Health | Nearly 30 Billion from Out-Licensing Deals! LaNova Medicines Acquired by SBP Group
After market close on July 15, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) announced that it will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million. Combined with the 4.91% stake already acquired through participation in LaNova's Series C financing, LaNova Medicines will become a wholly-owned subsidiary of Sino Biopharm upon completion of the transaction.2025-07-16 -
Company News
Blockbuster Deal! $500 Million Acquisition of LaNova Medicines to Further Accelerate SBP Group's Innovation and Internationalization
On July 15, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) made a major announcement that it will acquire 100% of LaNova Medicines Ltd. for a net consideration of approximately US$500 million.2025-07-15 -
Media Coverage
Healthcare Executive | SBP Group Makes Another Move: Acquires LaNova Medicines for RMB 3.5 Billion
The ecosystem of China's innovative drugs has taken another step towards diversification. On the afternoon of July 15, SBP Group announced that it will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million.2025-07-15 -
Media Coverage
China Securities Journal | Internationalization Strategy Accelerates as SBP Group Plans to Fully Acquire Innovative Drug Company LaNova Medicines
China Securities Journal, cs.com.cn (Reporter: Meng Peijia) - On July 15, Sino Biopharm announced that it will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million. Combined with the 4.91% stake acquired through participation in LaNova's Series C financing, LaNova Medicines will become a wholly-owned subsidiary of Sino Biopharm upon completion of the transaction.2025-07-15 -
Media Coverage
Xinhua News Agency | SBP Group to Acquire Innovative Drug Company LaNova Medicines for USD 500 Million
SBP Group will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million. Upon completion of the transaction, LaNova Medicines will become a wholly-owned subsidiary of SBP Group. LaNova Medicines' total out-licensing deals in the past three years amounted to nearly RMB 30 billion.2025-07-15




